{
    "clinical_study": {
        "@rank": "161350", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This non-interventional study will evaluate the routine use and the safety and efficacy of\n      Avastin (bevacizumab) as first-line treatment in patients with advanced ovarian cancer\n      (epithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma). Newly\n      diagnosed patients who are initiated on carboplatin/paclitaxel chemotherapy in combination\n      with Avastin will be followed for up to 15 months of treatment and 12 months of follow-up."
        }, 
        "brief_title": "BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Cancer, Peritoneal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Ovarian Neoplasms", 
                "Peritoneal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients with newly diagnosed advanced epithelial ovarian cancer (EOC), fallopian\n             tube carcinoma (FTC) or primary peritoneal carcinomas (PPC) with indication for\n             first-line carboplatin/paclitaxel chemotherapy in combination with Avastin\n\n        Exclusion Criteria:\n\n          -  Contraindications for Avastin according to the Summary of Product Characteristics"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with newly diagnosed ovarian cancer (epithelial ovarian cancer, fallopian tube\n        carcinoma or primary peritoneal carcinomas) with indication for carboplatin/paclitaxel\n        chemotherapy in combination with Avastin"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01788995", 
            "org_study_id": "ML28355"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Innsbruck", 
                    "country": "Austria", 
                    "zip": "6020"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28355 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Bundesamt f\u00fcr Sicherheit im Gesundheitswesen (BASG)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Clinical/demographic patient characteristics at initiation of treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Duration of treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Treatment discontinuations/modifications", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01788995"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}